Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avastin Added To Tarceva/Gemcitabine Fails To Prolong Survival In Phase III Pancreatic Cancer Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche-sponsored trial did not meet the primary endpoint of overall survival, but did show some clinical benefits.

You may also be interested in...



Pfizer Oncology Head Charles Baum: An Interview With “The Pink Sheet” DAILY (Part 1 Of 2)

Pfizer VP and Oncology Therapeutic Head Charles Baum talks to “The Pink Sheet” DAILY in an exclusive interview about the pharma giant’s increasing research emphasis in cancer drugs, and about pipeline developments, including axitinib in pancreatic cancer and a CTLA4 inhibitor, tremelimumab, for melanoma.

Avastin Fails First-Line Pancreatic Cancer Trial, But Pancreatic Program Will Continue

Genentech and partner Roche await results from another first-line pancreatic cancer trial, AVITA, with enrollment slated to complete by year-end.

Biohaven Shoots For Oral CGRP Leadership As Nurtec ODT Gains Momentum

The firm’s acute migraine treatment Nurtec ODT generated $65m in 2020 after launching a year ago. Biohaven aims for Nurtec to become the leader in what could be a $4bn-$5bn category in the US.

Topics

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel